Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Comment by lscfaon Apr 23, 2021 7:36pm
109 Views
Post# 33060178

RE:RE:RE:RE:video interview

RE:RE:RE:RE:video interview

Synthetic thc/CBD is still the way to go.   


Nov 25, 2019 - QIXLEEF is the company’s first-generation cannabinoid therapeutic in development for treating advanced cancer patients with uncontrolled pain. The company believes a subset of the advanced cancer patient population prefers to consume cannabis in the traditional way, using dried flower bud as a drug product.  In early 2019, Tetra uncovered an impurity in the dried flower bud cannabis and worked diligently to find solutions to develop a pharmaceutical grade cannabis drug free of any traces of the impurity.  



MiningGospel wrote: There's something called the Entourage effect, where CBD +THC + Terpenes work in conjunction with each other to help with pain relief. Rafi Mechoulum has done a lot of work in this field

lscfa wrote:

More confusion:

CAUMZ is a synthetic drug and QIXLEEF is a plant-based drug. Why?

QIXLEEF has a fixed ratio of cbd:thc. What is CAUMZ mimicking as a synthetic?

Why not make QIXLEEF synthetically to ensure a fixed ratio? Can a grower (Aphria) really guarantee consistency with tight tolerances?  

 

 



 

lscfa wrote: Interviewer asked what is it that investors are not getting? Part of the answer is confusion on whether Tetra is a cannabis stock or a biotech stock. I would add there is confusion on what is difference between CAUMZ and QIXLEEF. Are they both synthetic cannabis drugs? If so, why is Aphria the manufacturer? Does Aphria make synthetic cannabinoids? 

 

 





<< Previous
Bullboard Posts
Next >>
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse